Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Daily weighing Clear all
Terminated Phase 2 Interventional Results available

Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

NCT01200602
View directory record Official record
Conditions
Anorexia, Weight Changes
Interventions
megestrol acetate, clinical observation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 23, 2026, 2:17 PM EDT
Terminated Phase 1 Interventional Results available

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

NCT03704298
View directory record Official record
Conditions
Relapsed/Refractory Large B-cell Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Drug · Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Palo Alto, California • Santa Monica, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional

Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

NCT05935514
View directory record Official record
Conditions
Diabetes Mellitus, Type 2 Diabetes, Obesity
Interventions
WW Intervention, Usual Care
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 69 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Stanford, California • Baton Rouge, Louisiana • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 23, 2026, 2:17 PM EDT
Terminated Phase 2 Interventional

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
View directory record Official record
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 23, 2026, 2:17 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Investigations of Botanicals on Food Intake, Satiety, Weight Loss, and Oxidative Stress

NCT01238887
View directory record Official record
Conditions
Obesity, Oxidative Stress
Interventions
Microcrystalline Cellulose placebo pill, Garcinia cambogia-derived hydroxycitric acid (2800 mg/day), Garcinia Cambogia derived Hydroxycitric Acid
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

NCT02582775
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone marrow infusion, Tacrolimus, Mycophenolate Mofetil, Donor mesenchymal stem cell infusions, Busulfan
Drug · Radiation · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675
View directory record Official record
Conditions
Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
7 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 23, 2026, 2:17 PM EDT
No Longer Available No phase listed Expanded access

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

NCT00162227
View directory record Official record
Conditions
HIV Infection
Interventions
Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
3 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 23, 2026, 2:17 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Intervention Examining Tracking With Mobile Devices

NCT02632461
View directory record Official record
Conditions
Obesity
Interventions
Podcasts, Mobile Diet Application, Bite Counter
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional

Exercise and Nutrition on Obese Microbiome

NCT04138303
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Exercise Protocol, Calorie-Restrictive Low Carbohydrate Diet (CR-LC), Ancestral Diet (AD)
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 23, 2026, 2:17 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

NCT03325166
View directory record Official record
Conditions
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lidocaine for Oxaliplatin-induced Neuropathy

NCT03254394
View directory record Official record
Conditions
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
Interventions
Lidocaine Hydrochloride, Placebo, FOLFOX regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 23, 2026, 2:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

NCT03934905
View directory record Official record
Conditions
Anthracycline Related Cardiotoxicity in Breast Cancer
Interventions
sulforaphane, Placebo Oral Tablet
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 23, 2026, 2:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

NCT00790842
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 23, 2026, 2:17 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

NCT05226494
View directory record Official record
Conditions
Glioma, Malignant
Interventions
fb-PMT
Drug
Lead sponsor
NanoPharmaceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 2:17 PM EDT
Terminated Phase 1 Interventional Results available

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT04478994
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
TEPEZZA, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 23, 2026, 2:17 PM EDT
Active, not recruiting Not applicable Interventional

Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD

NCT06496542
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney
Interventions
Daily caloric restriction, Standard advice control
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

NCT00396877
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel (SR25990), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 92 Days
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 23, 2026, 2:17 PM EDT
Recruiting Phase 2 Interventional

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

NCT03579875
View directory record Official record
Conditions
Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
Interventions
Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan
Drug · Device
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 23, 2026, 2:17 PM EDT
Terminated Phase 3 Interventional Results available

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

NCT00836875
View directory record Official record
Conditions
Invasive Aspergillosis
Interventions
Voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 23, 2026, 2:17 PM EDT
Recruiting Phase 2 Interventional

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT03412877
View directory record Official record
Conditions
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R))
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparative Effectiveness Study Evaluating the Effects of Thermogenic Supplements on Body Composition

NCT01423019
View directory record Official record
Conditions
Weight Loss
Interventions
Advantra Z, Advantra Z + Naringin + Hesperiden, Sugar pill
Dietary Supplement · Other
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Sep 23, 2026, 2:17 PM EDT